AMD +4.9% on upgrade, COIN +4.3% on Goldman raise, MRK +3.8% on melanoma data

Tuesday's session closed with the 10-year Treasury at 4.70% and the VIX at 15.8 — rates elevated but range-bound, the options market unreflective of near-term stress. Against that backdrop, three equity moves of 3% or more arrived with named catalysts, and Home Depot filed its formal quarterly earnings document.

$HD — Q2 2026 Form 10-Q filed

Home Depot's Q2 2026 Form 10-Q arrived Tuesday, adding the formal financial filing to the earnings picture this desk first reported on August 18. The 10-Q includes management's updated business-conditions analysis and forward-looking commentary for the second half of fiscal 2026. Any material deviation from the initial earnings release will appear in the next issue.

$AMD +4.9% — Raymond James upgrade to strong buy

Raymond James lifted Advanced Micro Devices to strong buy from outperform Tuesday, adding institutional weight to a thesis that has gathered sell-side momentum in recent weeks. The upgrade is a discrete event; at least one separate analysis has put a 40% additional upside case on the stock from current levels. A competing view argues that even if $AMD hits its AI growth targets through 2030, it may not outperform the broader market from here. The upgrade moved the tape; the valuation debate underneath it is live.

$COIN +4.3% — Goldman Sachs reiterates buy, Bitcoin above $68,000

Goldman Sachs reiterated its buy rating on Coinbase and raised its price target Tuesday, pointing to rising crypto trading volumes and emerging revenue from prediction markets. Bitcoin's move above $68,000 — its highest level since early June — provided the broader sector lift. Stablecoin-adjacent names moved in sympathy: SoFi gained roughly 3% on similar positioning. Goldman's note identifies new revenue streams as part of the $COIN bull case; those streams have not yet produced the earnings numbers that would confirm the thesis.

$MRK +3.8% — Melanoma pipeline, post-trial repricing

$MRK added 3.8% Tuesday, extending the run that began with the August 19 pivotal readout on intismeran autogene, its individualized mRNA melanoma vaccine. The stock had already gained 19% in the month preceding today's session; Tuesday's close registered a 52-week high. The open question is whether intismeran can extend Keytruda's commercial runway as the PD-1 inhibitor faces approaching biosimilar exposure. Tuesday confirmed the market is still working through that repricing.

---

Filings desk. At $AMZN, the AWS chief executive sold $3.8M in company shares; no corporate event preceded the transaction in the public record. At $PLTR, a senior executive sold $86.1M in company shares — substantially larger than the $2.8M director transaction covered here on August 20, lifting total recent insider exit volume at PLTR to a level worth tracking as an ongoing beat.

---

What we set aside. One annual-meeting filing and twelve disclosures predating the 36-hour freshness window were held back today. Three tickers in the sweep — BRK.B, COST, and PLD — produced no filings or news within the window. Several Monday stories already ran in yesterday's issue and were ineligible for repeat treatment.

The desk is watching analyst response to $HD's Q2 Form 10-Q for any management commentary on consumer spending conditions in the second half of 2026.